$ETSY

Silverman Josh sold $3.1M of ETSY

Silverman Josh sold 39,161 shares of ETSY INC (ETSY) at $79.00 ($3.09M total) on 2026-07-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Silverman Josh
Published Jul 14, 2026, 8:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 14, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ETSY
Neutral
medium confidence
Mentioned
$ETSY
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ETSYNeutralLow
01

Why it matters

The only new fact is the disclosed sale size, price ($79.00/share), and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note incremental insider selling, but the 10b5-1 structure and lack of fundamental updates make this more of a monitoring item than a catalyst.

03

What to watch

The article provides no context on whether the sale was part of a larger scheduled program, nor does it indicate any concurrent changes in guidance, contracts, or strategy.

Relevance 5/10Novelty 3/10Timing: Filed on 2026-07-14, disclosing a 2026-07-10 insider sale.

Background

The article is an SEC Form 4 insider transaction disclosure for ETSY, reported by director Josh Silverman.

Company-level read

Ticker impact

$ETSYNeutralMedium confidence
Context

SEC Form 4 shows director Josh Silverman sold 39,161 shares of ETSY for about $3.09M under a 10b5-1 plan.

Expected impact

Likely limited immediate impact; any effect would be modest and short-lived unless accompanied by other disclosures.

Evidence & confidence

The filing is a routine insider sale with stated 10b5-1 pre-arrangement, and it does not include new operating, financial, or regulatory information.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can still be interpreted by some traders as a mild caution signal, especially if paired with other negative catalysts.

Key entities

  • ETSY

    Issuer of the Form 4 insider transaction; director Josh Silverman sold 39,161 shares for about $3.09M.

  • Josh Silverman

    Director of ETSY who executed an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WMTMed

Retailers Report AI-Driven Sales, Bigger Baskets in Q2 Earnings

Walmart, Amazon, and Target reported Q2 earnings showing AI-driven sales growth. Walmart's eCommerce grew 23%, with AI assistant users spending 40% more. Amazon's Alexa for Shopping saw active users nearly double. Target's digital traffic from AI platforms grew over 3.5x faster than the industry average. Albertsons saw a 10-26% increase in order value with AI tools. Shopify's AI-referred traffic and orders tripled, but AI's impact on discovery-driven retail remains uncertain.

$ETSYHigh

Bank of America Resets Etsy Stock Price Target After Event

Bank of America upgraded Etsy to Buy, raising its price target to $105 from $88, citing structural growth. The bank expects mid-single-digit gross merchandise sales growth, higher profitability, and increased shareholder returns. Etsy's new management team is seen as key to reinvigorating growth. BofA raised its fiscal 2027 estimates for gross merchandise sales, EBITDA, and EPS.

$DEMed

Premarket movers: Deere jumps following upbeat Q3, Wolfspeed plunges

Deere shares rose 5.1% after reporting stronger-than-expected Q3 results, with EPS of $5.10 and net sales of $11B. CrowdStrike fell 2.8% following its CTO's departure. Advance Auto Parts dropped 15.9% due to lower normalized earnings. Etsy gained 3.9% after a BofA upgrade. Ultragenyx surged 11.1% on FDA approval for a gene therapy. Moderna fell 13% after a prior surge. Wolfspeed plunged 10.5% on wider-than-expected Q4 loss. Webull rose 13.8% on strong Q2 results.